Abstract
Much progress has been made in the diagnosis and treatment of Hodgkin's lymphoma, which has become a highly curable malignancy. However, prolonged survival makes clinicians pay more attention to long-term toxicities of treatment. Consequently, individualized treatment based on disease stage and risk factors is a research hotspot at present. This article reviews recent advances in the individualized treatment of early-stage classical Hodgkin's lymphoma. Key words: Hodgkin disease/radiotherapy; Hodgkin disease/chemotherapy; Risk assessment; Tomography, positron-emission
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
